Rankings
▼
Calendar
CCCC Q1 2024 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CCCC
C4 Therapeutics, Inc.
$243M
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
-19.2% YoY
Gross Profit
$3M
100.0% margin
Operating Income
-$32M
-1060.2% margin
Net Income
-$28M
-933.2% margin
EPS (Diluted)
$-0.41
QoQ Revenue Growth
-6.8%
Cash Flow
Operating Cash Flow
-$18M
Free Cash Flow
-$18M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$398M
Total Liabilities
$140M
Stockholders' Equity
$258M
Cash & Equivalents
$90M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3M
$4M
-19.2%
Gross Profit
$3M
-$25M
+112.0%
Operating Income
-$32M
-$36M
+11.1%
Net Income
-$28M
-$35M
+18.5%
← FY 2024
All Quarters
Q2 2024 →